Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates

AbstractAlong with cognitive decline, 90% of patients with dementia experience behavioral and psychological symptoms of dementia, such as psychosis, aggression, agitation, and depression. Atypical antipsychotics are commonly prescribed off-label to manage certain symptoms, despite warnings from the regulatory agencies regarding the increased risk of mortality associated with their use in elderly patients. Moreover, these compounds display a limited clinical efficacy, mostly owing to the fact that they were developed to treat schizophrenia, a disease characterized by neurobiological deficits. Thus, to improve clinical efficacy, it has been suggested that patients with dementia should be treated with exclusively designed and developed drugs that interact with pharmacologically relevant targets. Within this context, numerous studies have suggested druggable targets that might achieve therapeutically acceptable pharmacological profiles. Based on this, several different drug candidates have been proposed that are being investigated in clinical trials for behavioral and psychological symptoms of dementia. We highlight the recent advances toward the development of therapeutic agents for dementia-related psychosis and agitation/aggression and discuss the relationship between the relevant biological targets and their etiology. In addition, we review the compounds that are in the early stage of development (discovery or preclinical phase) and those that are currently being investigated...
Source: CNS Drugs - Category: Neurology Source Type: research

Related Links:

Abstract BACKGROUND: The significance of palliative care consultation in psychiatry is unclear. ACTUAL CASE SERIES: Analysis of the introduction of palliative care consultation in a large psychiatric hospital. POSSIBLE COURSES OF ACTION: Continue without offering, survey the need for or offer palliative care consultation, and analyse its introduction. FORMULATION OF A PLAN: Palliative care consultation was established and details including patient age, department, diagnosis, main problem, solution and discharge were analysed during the first 2 years. OUTCOME: Two consultations in the fir...
Source: Palliative Medicine - Category: Palliative Care Authors: Tags: Palliat Med Source Type: research
This article summarizes the milestones in the development of lumateperone leading to this first approval for the treatment of schizophrenia.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionsOur results indicate the prevalence of multiple comorbidities varies across the lifespan in DS, and in adults, rates for psychiatric comorbidities show different patterns for males and females relative to expected population rates. Further, most health comorbidities are not associated with poorer cognitive outcomes in DS, apart from autism and epilepsy. It is essential for clinicians to consider such differences to provide appropriate care and treatment for those with DS and to provide prognostic information relating to cognitive outcomes in those with comorbidities.
Source: Journal of Neurodevelopmental Disorders - Category: Neurology Source Type: research
The barrier between mind and body appears to be crumbling. Clinical practice and public perception need to catch upUnlikely as it may seem, #inflammation has become a hashtag. It seems to be everywhere suddenly, up to all sorts of tricks. Rather than simply being on our side, fighting infections and healing wounds, it turns out to have a dark side as well: the role it plays in causing us harm.It ’s now clear that inflammation is part of the problem in many, if not all, diseases of the body. And targeting immune or inflammatory causes of disease has led to a series of breakthroughs, from new treatments for rheumatoid ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Mental health Psychiatry Multiple sclerosis Depression Dementia Society Medical research Science UK news Alzheimer's Parkinson's disease Schizophrenia Source Type: news
__________ We are pleased to share a fantastic professional development opportunity offered by the Luria Neuroscience Institute and featuring renowned neuropsychologist Elkhonon Goldberg, Ph.D., ABPP. Inaugural 5‑day Goldberg Brain-Mind Symposium (February 17–21st, 2020): Dr. Goldberg has been a frequent visitor to Bali for 30 years and is currently engaged in cross-cultural neuroscience research with two major Indonesian universities. He personally designed this unique and comprehensive event to discuss cutting edge cognitive neuroscience and state-of-the-art clinical insights with a small group of participants in...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Professional Development Bali discount code Elkhonon-Goldberg Executive-Functions frontal-lobes Goldberg Brain-Mind Symposia Luria Neuroscience Institute neuropsychologist webinar sequence Source Type: blogs
Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein that is overexpressed in many pathological states. Although, like many other immune molecules, ICAM-1 plays only a limited role in the abundant concert of the immune response, it may be more important than we realize. In the central nervous system (CNS), ICAM-1 is expressed in microglial cells and astrocytes and in endothelial cells in the white and gray matter of the human forebrain. It is of particular interest in psychiatric disorders for two reasons: It has a key function for the blood–brain barrier, which plays an important role in the bi...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
What exactly is psychosis? What happens in the brain of a person with schizophrenia who is hallucinating? Schizophrenic Rachel Star Withers shares her personal hallucinations and delusions and Dr. Joseph Goldberg, who specializes in researching what goes on in the brain when someone is experiencing psychosis, joins to break down how the brain functions during psychotic episodes. Host Rachel Star Withers, a diagnosed schizophrenic, and co-host Gabe Howard delve into these intense subjects in this episode of Inside Schizophrenia.  Highlights from “Psychosis in Schizophrenia” Episode [02:13]  Rachel, do...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Brain and Behavior Disorders General Inside Schizophrenia Mental Health and Wellness Active psychosis Delusions Delusions Hallucinations Living with Schizoprenia Mental Disorder Mental Illness Psychology psychotic Psychotic Break Source Type: blogs
Abstract Herein we describe a focused set of new arylpiperazine derivatives as potential broad-spectrum antipsychotics. The general structure contains a quinolinone-like moiety, an arylpiperazine moiety, and a five-atom linker. Among them, 7-(5-(4-(benzo[d]isothiazol-4-yl)piperazin-1-yl)pentyl)quinolin-2(1H)-one (S6) shows a promising preclinical profile. Compound S6, characterized by partial D2 R agonism, 5-HT1A R agonism, 5-HT2A R antagonism, and blockade of SERT activities, was found to decrease psychosis- and depressive-like symptoms in rodents. The polypharmacological profile of S6 could provide opportunities...
Source: ChemMedChem - Category: Chemistry Authors: Tags: ChemMedChem Source Type: research
Publication date: Available online 27 September 2019Source: Brain, Behavior, and ImmunityAuthor(s): Jane Pei-Chen Chang, Kuan-Pin SuAbstractThe ‘monoamine hypothesis’ is insufficient in approaching the aetiology of psychiatric disorders or in developing novel therapies. Accumulating evidence suggests that inflammatory regulation plays an important role in pathophysiology and therapeutic mechanism across the major psychiatric disorders. “Inflammation theory” might not be the full answer for the big picture of mental disorders, but it might explain high occurrence of somatic symptoms and comorbidity o...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
More News: Brain | Clinical Trials | Dementia | Depression | Drugs & Pharmacology | Neurology | Psychology | Schizophrenia | Study | Warnings